Mundipharma- Newsletter (SHAFI REZA)

PHARMANEWS
Article created, constructed & designed by Shafi Reza
VOLUME 12 - ISSUE 5
APRIL 2021
MUNDIPHARMA
NETWORK
Why Work With
Mundipharma?
The Mundipharma network’s ability to address
real world patient needs is informed
by leading-edge research, with direct input
from patients and patient organizations,
alongside physicians, payers and other
healthcare providers.
We ask different and challenging questions
and work collaboratively with external
experts to add value to our partner’s assets.
This newsletter outlines our current therapy
areas and portfolio of medicines, primarily
in relation to the Mundipharma
network across Europe. It also gives more
information about our future strategies for
each therapy area, and explains how we are
working to achieve these strategies.
“Mundipharma is at an exciting point in its
transformational journey. One focussed on
creating a culture of innovation and differentiation,
where every individual employee
counts and can make a real difference.”
Marc Princen, Global CEO
LATEST NEWS INSIDE
For more information, please visit: www.mundipharma.com

VOLUME 12 - ISSUE 5
APRIL 2021
WHO WE ARE &
WHAT WE DO
RESEARCH & DEVELOPMENT
Across the Mundipharma global network of independent
associated companies, we have a strong track record of
providing medicines that meet real-world patient needs.
Often, we have been successful by looking beyond the
traditional areas of focus for pharmaceutical companies.
We are never afraid to explore needs that have been
overlooked by others.
Our approach has enabled us to become global leaders
in the field of pain management. We are now committed
to using the same patient-focused methodology to make
medicines available across our core areas of expertise –
pain, respiratory, oncology and biosimilars.
While a deep understanding of individual patient needs
informs everything we do, we also strive to broaden our
appreciation of the challenges healthcare providers face
in trying to fulfil their responsibilities to society as a whole.
Mundipharma is a global network of independent
associated companies that research, develop and
manufacture innovative pharmaceutical medicines and
consumer healthcare products.
We are an agile and fast-paced company seeking to
increase access to health care through programmes and
effective partnerships.
We are forward-looking and dedicated to bringing innovative
treatments to many of the world’s most challenging
conditions and diseases including: Pain Management
& Supportive Care, Consumer Health, Anti-Infectives,
Biosimilars, CNS, Diabetes, Oncology, Ophthalmology,
Respiratory and transplantation immunity.
We make a difference to patient lives by delivering
value to healthcare professionals in 120+ countries across
Africa, Asia Pacific, Canada, Europe, Latin America and the
Middle East.
Our guiding principles, centred around Integrity and
Patient-Centricity, are at the heart of everything we do.
We encourage our people to think differently and our
inclusive culture of continuous learning and collaboration
make Mundipharma a great place to work.
Alliances are central to the way the Mundipharma network
of independent associated companies does business.
As a network, we make alliances for value, not volume –
establishing a limited number of long-term relationships
with companies who share our commitment to meeting
patient needs.
To every relationship, we bring risk appetite,
entrepreneurial drive and a willingness to challenge
conventional wisdom, all underpinned by our proven
industry expertise.

WORKING
OUR APPROACH TO ALLIANCES
What binds all of our diverse partners together is a willingness to share in our mission to create sustainable
benefits and value for all stakeholders in the modern healthcare environment.
ENVIRONMENT
Mundipharma is committed to providing products which give people the best possible quality of life. This starts
with a vision: a trusted healthcare product.. Building on our strong network of stakeholders, we want to continue
supporting healthcare professionals and healthcare consumers with innovative and effective products to meet their
needs.
But we are driven by more than just a vision. Our relationships with patients, carers, doctors, nurses, pharmacists
and distributors are at the centre of how we operate. Our five core values guide every decision we make and define
who we are as an organisation.
OUR VALUES:
Integrity
We act ethically, professionally and responsibly.
Most pharmaceutical companies operate through alliance partners
and the larger multinationals will typically bring a multitude of business
alliances on board in any given year, however, with many being allowed
to fall by the wayside. As a network we take a different approach. The
Mundipharma global network of independent associated companies
believes that every alliance partner and every medicine we work with
deserves our full commitment, so as a network we aim to establish no
more than a handful of agreements each year.
Before embarking on a new alliance we do our homework:
asking questions and challenging perceptions, with the aim of finding
opportunities both “home run” assets as well as opportunities that
might previously have been undervalued or overlooked. For example,
could the medicine meet patient needs more cost-effectively than existing
solutions? Or are there new markets that could be accessed via
the Mundipharma network?
Our alliances are long-term arrangements, typically 10 years or more,
based on high levels of interaction and transparency in the way
information is shared. While we do focus on our four core therapy
areas of pain, respiratory, oncology and biosimilars, we are also flexible
when it comes to the therapy areas we engage in. If the network does
not have an existing business unit in place and wants to engage in a
new therapy area, it will build infrastructure to support the sourcing of
new assets.
Customer Focus
We understand, care and deliver.
Agility
We act quickly and decisively.
Respect
We have due regard for the rights, views and feelings of others.
Mundipharma is an independent healthcare company with global reach and connections. Unlike others, we are
agile and fast. Masters of our own destiny, we encourage people to shape the company as we grow.
Our products help people lead fuller, longer lives. Driven to make a difference, we continually search for new
products that meet genuine health needs.
We give back by supporting people in need through corporate contributions and we work as a team to help local
communities.
We are respectful, ethical, and entrepreneurial. Mundipharma is not a place to fly under the radar; we celebrate
achievement and reward impact. We challenge our employees to improve and grow.
Successful business partnerships don’t happen by accident.
As a global network of independent associated companies, we
never underestimate the focus and commitment necessary to make
alliance partnerships work for the long-term. Once the collaboration
is formally under way, all our actions and decisions are driven by the
overriding objective of maintaining a strong and successful relationship
– one that enables both partners to achieve their goals.
From an alliance partner’s perspective, our core appeal lies in the
network’s ability to identify potential in medicines and then work
collaboratively to accelerate their release. As a business founded by
physicians, we remain highly attuned to the rapidly evolving primary
and secondary healthcare landscapes and, in particular, to the opportunities
for value creation this presents. We have the commitment and
resources to back our judgment and stay the course for the long-term.
We believe alliance management should begin even before a partnership
is formally executed, because the earlier we can understand
our potential partner’s collaboration and corporate development
objectives – as well as its culture and ways of working – the more
effectively we can build our business alliance. We will bring together
cross-functional teams to prepare the ground for day one – a process
that includes identifying team members, setting appropriate internal
governance structures and managing the relationship.

“NOT TODAY
COVID-19”
PHARMA NEWS
VOLUME 12 - ISSUE 5
APRIL 2021
EFFECTIVENESS AGAINST
COVID-19 VIRUS
Laboratory Studies Confirm BETADINE® Antiseptic Products’ Effectiveness Against
COVID-19 Virus Study published in Infectious Disease and Therapy Journal
Mundipharma today announced that laboratory testing at the Duke-NUS Medical School in
Singapore, has confirmed the effectiveness of its BETADINE® antiseptic products against the novel
coronavirus (SARS-CoV-2) which causes COVID-19 disease.
Testing has demonstrated BETADINE’s® strong in-vitro virucidal activity, killing 99.99% of the SARS-
CoV-2 virus in 30 seconds. The products subjected to testing were: BETADINE® antiseptic products,
namely Solution (10% PVP-I), Skin Cleanser (7.5% PVP-I), Gargle and Mouthwash (1.0% PVP-I) and
Throat Spray (0.45% PVP-I).
The research has been published in the respected Infectious Disease and Therapy Journal on 08 July
2020. “These results confirm our view that BETADINE® antiseptic products, used appropriately and
in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections,
including COVID-19,” said Raman Singh, CEO Mundipharma.
“It also provides the medical community as well as consumers with a science-based assurance that they are using a
product that is a proven defence against COVID-19,” he added.
About BETADINE
The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years
to prevent and treat infections.
Over the last few years, Mundipharma has expanded the BETADINE® range of products to include povidone-iodine
and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper
respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand
hygiene.
In-vitro and clinical studies have demonstrated that BETADINE povidone iodine kills a broad range of bacteria, viruses and
fungi including antibiotic-resistant strains.

PROJECT STRATEGY
I had two fundamental objectives for this newsletter
My first objective was to come up with a strategy that
the newsletter could follow. Something that would
be a refresh and revamp from the existing ‘Latest
News’ PDF that opens when you click an article on the
‘Latest News’ segment on the current website.
My second objective was to ensure that the
design followed a structure, that structure being; set
colours, boxes and brand guidelines that followed
the original Mundipharma theme. I felt this would be
great for online presence.
The strategy that I approached this task with involved
in-depth trial and error on layouts. This was vital for
me to execute with precision from the beginning
because throughout my experience, I have learned
that even if the content of the magazine is engaging
- if the layout is unappealing and hard for the reader
to navigate through, this leads to a greater chance of
them losing interest very early on.
I utilised my ‘user experience’ training to understand
how text & image boxes would be laid out and how to
structure the text on each page with the right amount
of images and colour, giving that particular page a
strong balance aesthetically.
The overall reason as to why I took the magazine
in this direction is because I felt that it would be an
adaptable theme and layout for any storyline or topic.
This makes the design versatile and easily adjustable,
resulting in efficiency on the quick turn around time
when releasing new weekly/monthly newsletter.
With people having even less time and patience now
than before to get to the ‘interesting part’ of the
content, it was important to make things more ‘visual’
with larger page to page images and sub-images as
well as infographic diagrams.
From my experience of creating magazines in
collaboration with award winning digital marketing
agency ‘Champions PLC’, I learned that visual communication
persuades readers to read the text to find
out what the engaging picture is about. Similarly, even
if more text was required, with this layout, this can
easily be done without the page looking overwhelming
or overflowing with text.
During my second stage interview at Mundipharma
with the Senior Vice President Communications, I
learned that there will be a new website released and
so I kept this in mind when coming up with a strategy
to make the ‘Latest News’ segment visually more aesthetic,
while keeping it professional.
I did this by deciding to use an external platform
(Yumpu) to upload the newsletter in a digital book
format, similar to the format of books on a kindle with
the swiping page motion which would allow the reader
to flick through the page of the newsletter, download,
print or share it with their followers with ease.
The URL link would then be fed through to the
designated web page or social media platform, making
it easy for the audience to access weekly/monthly
newsletters straight to their devices.
This platform also enables social sharing.
PLAN OF ACTION
MUNDIPHARMA INTERNATIONAL
LIMITED
205 Cambridge Science Park Road,
Milton, Cambridge
CB4 0GZ
Tel: +44 (0)1223 424211
www.mundipharma.com
Design Restructure Plan User experience & Functionality Design Aesthetics Social engagement
Once I gathered my knowledge and strategy for these four areas, I was able to get on with the design easily,
knowing I had a plan, knowing what my objectives were and knowing what was required to achieve these goals.
If I am the chosen candidate for this position, when given with feedback from management and colleagues on
campaigns like this one, I will be diligent yet assertive in my approach to ensure that there is always a significant
change and improvement in the dynamics of the content created, resulting in Mundipharma to excel with
content, user experience, networking and online presence,
Link to professional portfolio:
https://drive.google.com/drive/folders/1pomtShvy-LGJ2Z_Xhpl0nI5x-Ttt4wdV?usp=sharing
(The files have been categorised in ‘project types’ for user convenience)